IntraPace Plans Anti-Obesity Stomach Stimulator Pivotal Trial
This article was originally published in The Gray Sheet
Executive Summary
IntraPace is in discussions with FDA about an investigational device exemption for its abiliti anti-obesity stomach pacemaker system, and hopes to begin a U.S. pivotal trial by early 2012, according to the company.
You may also be interested in...
Obesity 2015: Less Invasive Options Will Drive Growth In Market Hungry For Solutions
Nearly half of the world’s adult population will be overweight or obese by 2030 and obesity is tied to more than 40 diseases. Enterprising companies are heeding the call with increasingly less invasive weight loss devices, while an amenable regulatory environment means the marketplace will welcome some of these innovations in 2015.
MetaCure Implant For Type 2 Diabetes: Overseas Trials To Wrap Up By 2012
MetaCure plans to wrap up three overseas trials by the end of 2012 for its DIAMOND electrostimulator implant for type 2 diabetes in obese patients and will begin a pivotal U.S. trial within the next couple of years to support a PMA submission for type 2 diabetes.
MetaCure Implant For Type 2 Diabetes: Overseas Trials To Wrap Up By 2012
While the current plan for the U.S. market is focused on an eventual PMA submission for type 2 diabetes, the firm may also pursue an obesity indication.